Sign in Subscribe
Class action lawsuits

Rocket Pharmaceuticals Faces Securities Class Action Lawsuit Over Alleged Misleading Statements

Strategic Insights

— 2 min read

Investors in Rocket Pharmaceuticals who suffered significant losses after the company's Phase 2 trial for Danon disease was placed on clinical hold by the FDA are now being encouraged to seek compensation. The company's shares plummeted over 60% in a single day after the announcement, wiping out substantial investor wealth. A securities class action lawsuit has been filed on behalf of investors who purchased Rocket Pharmaceuticals securities between February 27 and May 26, 2025, alleging that the company made materially false and misleading statements regarding the safety, efficacy, and clinical protocol of its RP-A501 Phase 2 pivotal trial.

Key Takeaways:

  • A securities class action lawsuit has been filed against Rocket Pharmaceuticals, alleging that the company misled investors about the safety and progress of its RP-A501 gene therapy trial for Danon disease.
  • The lawsuit centers on whether the company provided materially false and misleading statements regarding the safety, efficacy, and clinical protocol of its RP-A501 Phase 2 pivotal trial.
  • Plaintiffs allege that while Rocket publicly highlighted its advances and expressed confidence in meeting trial endpoints, it failed to alert investors to significant protocol changes and known risks of Serious Adverse Events (SAEs), including patient deaths.
  • On February 27, 2025, Rocket told investors it had "made strong progress in advancing our gene therapy" and cited the Phase 1 results of RP-A501 as evidence of "safety and meaningful efficacy up to five years."
  • The company's shares closed at $9.40 that day, buoyed by these statements and later updated references to www.ClinicalTrials.gov for more detail about the ongoing Phase 2 study.
  • Plaintiffs claim that behind the scenes, Rocket had amended the study protocol months earlier to introduce a novel immunomodulatory agent in the trial's pretreatment regimen-an adjustment allegedly not disclosed to shareholders at the time.
  • The company's narrative unraveled on May 27, 2025, when Rocket revealed in an update call that the U.S. Food and Drug Administration had placed a clinical hold on the RP-A501 trial following a patient's SAE and subsequent death.
  • The stock price plummeted 62% in a single day and down 75% from its February 27, 2025 closing price.
  • The lawsuit contends that Rocket's earlier statements created an artificially inflated stock price, and investors suffered heavy losses once the undisclosed risks and protocol changes became public.
  • The deadline to seek lead plaintiff status is August 11, 2025.

Statistics:

  • 62%: the amount the company's shares plummeted in a single day after the clinical hold was announced.
  • 75%: the decrease in the company's stock price from its February 27, 2025 closing price.
  • $9.40: the closing price of Rocket Pharmaceuticals shares on February 27, 2025.
  • February 27, 2025 - May 26, 2025: the period during which investors who purchased Rocket Pharmaceuticals securities may be eligible to participate in the class action lawsuit.
  • August 11, 2025: the deadline to seek lead plaintiff status in the securities class action lawsuit.

Sources:

  • Hagens Berman San Francisco, California, press release dated August 7, 2025.
  • Newsfile Corp. press release, August 7, 2025.
  • SEC Whistleblower program.

Read more